Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
10,000+ US Securities
Unlisted Companies not available on US Stock Exchanges
Professionally managed portfolios, designed by Vested’s research team
Get exposure to 50+ countries via global funds managed by the world’s top fund managers
Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Connect with investors, share insights, and grow together
Stay up to date on latest investing trends and other announcements
Explore our range of financial tools to streamline your investment planning
A structured, comprehensive way to understand global investing
Read about our journey and get to know the leadership team at Vested
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidate is AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical trial for use in severe pediatric onset Crohn's disease. The company also develops AEVI-005, a monoclonal antibody, which is in preclinical research program for the treatment of auto-immune pediatric disease. In addition, it focuses on evaluating the anti-seizure activity of AEVI-004 in a preclinical model as part of the National Institutes of Health Epilepsy Treatment Screening Program. It has a development and option agreement with Kyowa Hakko Kirin Co., Ltd. related to AEVI-002 and AEVI-005. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania. As of February 3, 2020, Aevi Genomic Medicine, LLC operates as a subsidiary of Cerecor Inc. more
| Time Frame | GNMX | S&P500 |
|---|---|---|
| 1-Week Return | - | 2.71% |
| 1-Month Return | - | 7.5% |
| 3-Month Return | - | 6.55% |
| 6-Month Return | - | 7.98% |
| 1-Year Return | - | 26.52% |
| 3-Year Return | - | 79.06% |
| 5-Year Return | - | 78.03% |
| 10-Year Return | 435.53% | 257.99% |
| Time Frame | GNMX | S&P500 |
|---|---|---|
| 1-Week Return | 0.00% | 303.20% |
| 1-Month Return | 0.00% | 141.07% |
| 3-Month Return | 0.00% | 29.34% |
| 6-Month Return | 0.00% | 16.85% |
| 1-Year Return | 0.00% | 26.52% |
| 3-Year Return | 0.00% | 21.43% |
| 5-Year Return | 0.00% | 12.23% |
| 10-Year Return | 18.27% | 13.60% |
| Sector | Weight |
|---|---|
|
Health Care
|
100.00% |
Aevi Genomic Medicine LLC (GNMX) share price today is $25.1469.
Yes, Indians can buy shares of Aevi Genomic Medicine LLC (GNMX) on Vested. To buy GNMX from India, you can open a US Brokerage account by signing up on Vested. The account opening process is completely digital and secure, and takes 3-5 minutes to complete.
Yes, you can purchase fractional shares of Aevi Genomic Medicine LLC (GNMX) on Vested. You can start investing in Aevi Genomic Medicine LLC (GNMX) with a minimum investment of $1.
The 52-week high price of Aevi Genomic Medicine LLC (GNMX) is $. The 52-week low price of Aevi Genomic Medicine LLC (GNMX) is $.
The stock symbol (or ticker) of Aevi Genomic Medicine LLC is GNMX.
Yes, you can setup SIP in Aevi Genomic Medicine LLC shares. Follow the below steps to create the SIP:
Here is the historical performance of GNMX on the Vested app.
The expense ratio of Aevi Genomic Medicine LLC (GNMX) is .
Link copied